| 摘要 |
The present invention provides a fusion molecule comprising a first domain and a second domain, wherein said first domain comprises the HLA-DR alpha 2 domain or a fragment thereof. Said fusion molecule is capable of modulating the T-cell mediated immune response. Furthermore, pharmaceutical compositions comprising said fusion molecules for the treatment of various diseases such as graft versus host disease, autoimmune diseases, allergic diseases, infectious diseases and tumors in a subject are described. |
